Sign Out
375 mg tablet: Hypersensitivity to Ranolazine. Severe renal impairment (creatinine clearance <30 mL/min). Moderate or severe hepatic impairment. Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Concomitant administration of Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.
500 mg tablet: Ranolazine is contraindicated in patients with Hypersensitivity to the active substance or to any of the excipients, patients taking strong inhibitors of CYP3A, patients taking inducers of CYP3A and patients with clinically significant hepatic impairment.
